keyword
MENU ▼
Read by QxMD icon Read
search

HPV treatment

keyword
https://www.readbyqxmd.com/read/28342482/treatment-outcomes-in-veterans-with-hpv-positive-head-and-neck-cancer
#1
Aaron J Feinstein, Sophie G Shay, Elena Chang, Michael S Lewis, Marilene B Wang
OBJECTIVES: Head and neck squamous cell carcinoma (HNSCC) caused by the human papilloma virus (HPV) has an improved prognosis relative to HPV-negative tumors. Patients with HPV-positive disease may benefit from different treatment modalities in order to optimize survival and quality of life. We sought to investigate HPV-positive HNSCC within the military veteran population, and analyze the role of treatment modality in outcomes of patients with HPV-positive and HPV-negative tumors. METHODS: Patients diagnosed with HNSCC between January 1, 2010 and December 31, 2014 at one regional veterans health center were retrospectively examined...
March 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/28337474/cervical-cancer-prevention-in-el-salvador-cape-an-hpv-testing-based-demonstration-project-changing-the-secondary-prevention-paradigm-in-a-lower-middle-income-country
#2
Mauricio Maza, Karla Alfaro, Jillian Garai, Mario Morales Velado, Julia C Gage, Philip E Castle, Juan Felix, Silvana Luciani, Nicole Campos, Jane Kim, Rachel Masch, Miriam Cremer
•CareHPV tests were used to compare screen-and-treat and colposcopy management.•Screen-and-treat strategy with HPV testing was found to be very cost-effective.•CAPE has screened > 25,000 women in the Paracentral region.•Over 70% of screen-positive women received recommended treatment within six months.•CAPE is an example of public-private partnership resulting in paradigm change.
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28336131/modulating-the-dna-damage-response-to-improve-treatment-response-in-cervical-cancer
#3
L H Cossar, A G Schache, J M Risk, J J Sacco, N J Jones, R Lord
Cervical cancer is the fourth most common cause of cancer-related death in women worldwide and new therapeutic approaches are needed to improve clinical outcomes for this group of patients. Current treatment protocols for locally advanced and metastatic disease consist of ionising radiation and chemotherapy. Chemoradiation induces cytotoxic levels of DNA double-strand breaks, which activates programmed cell death via the DNA damage response (DDR). Cervical cancers are unique given an almost exclusive association with human papillomavirus (HPV) infection; a potent manipulator of the DDR, with the potential to alter tumour sensitivity to DNA-damaging agents and influence treatment response...
March 20, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28335889/human-papillomavirus-as-prognostic-marker-with-rising-prevalence-in-neck-squamous-cell-carcinoma-of-unknown-primary-a-retrospective-multicentre-study
#4
Lea Schroeder, Paolo Boscolo-Rizzo, Elisa Dal Cin, Salvatore Romeo, Lorena Baboci, Gerhard Dyckhoff, Jochen Hess, Carlota Lucena-Porcel, Anne Byl, Nikolaus Becker, Laia Alemany, Xavier Castellsagué, Miquel Quer, Xavier León, Manuel Wiesenfarth, Michael Pawlita, Dana Holzinger
Patients with neck squamous cell carcinomas of unknown primary tumour (NSCCUP) present with lymph node metastasis without evidence for a primary tumour. Most patients undergo an aggressive multimodal treatment, which induces severe, potentially unnecessary toxicity. Primary tumours of NSCCUP can be hidden in the oropharynx. Human papillomavirus (HPV) is causally involved in a subgroup of oropharyngeal squamous cell carcinomas (OPSCC) associated with early lymph node metastasis and good prognosis. Detection of markers for HPV transformation in NSCCUP could allow focussing on the oropharynx in primary tumour search and could be of value for choice and extent of treatment...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28334393/adjuvant-human-papillomavirus-vaccination-for-secondary-prevention-a-systematic-review
#5
Gregory R Dion, Stephanie Teng, Leslie R Boyd, Antonia Northam, Charlotte Mason-Apps, Dorice Vieira, Milan R Amin, Ryan C Branski
Importance: Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. Objective: To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinical disease across disease sites to serve as a platform for the management of HPV-related disease of the head and neck...
March 23, 2017: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/28333966/associations-of-human-papillomavirus-hpv-genotypes-with-high-grade-cervical-neoplasia-cin2-in-a-cohort-of-women-living-with-hiv-in-burkina-faso-and-south-africa
#6
Helen A Kelly, Jean Ngou, Admire Chikandiwa, Bernard Sawadogo, Clare Gilham, Tanvier Omar, Olga Lompo, Sylviane Doutre, Nicolas Meda, Helen A Weiss, Sinead Delany-Moretlwe, Michel Segondy, Philippe Mayaud
OBJECTIVE: To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). METHODS: Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later...
2017: PloS One
https://www.readbyqxmd.com/read/28333902/proteflazid%C3%A2-and-local-immunity-in-diseases-caused-by-human-papillomavirus-herpesvirus-and-mixed-urogenital-infections
#7
Vjacheslav Kaminsky, Viktor Chernyshov, Oleksandr Grynevych, Vasil Benyuk, Alla Kornatskaya, Miroslava Shalko, Igor Usevich, Oleg Revenko, Maxim Shepetko, Ludmila Solomakha
Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract. AIM: The aim of study was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia). MATERIALS AND METHODS: The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection - HSV-1, HSV-2 and chlamydia (Group 3)...
March 21, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28329527/acitretin-for-the-treatment-of-recalcitrant-plantar-warts
#8
Deep Joshipura, Ari Goldminz, Jacqueline Greb, Alice Gottlieb
Plantar warts caused by human papilloma virus (HPV)may be challenging to treat when conventionalmodalities fail. We report a case of severely recalcitrantplantar warts, successfully treated with oral acitretinand topical 40% urea cream.
March 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28328302/pembrolizumab-for-platinum-and-cetuximab-refractory-head-and-neck-cancer-results-from-a-single-arm-phase-ii-study
#9
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, Francis Worden, Stephen V Liu, Jill Gilbert, Nabil F Saba, Jared Weiss, Lori Wirth, Ammar Sukari, Hyunseok Kang, Michael K Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D Cheng, Robert Haddad
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks...
March 22, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28325688/current-and-emerging-molecular-tests-for-human-papillomavirus-related-neoplasia-in-the-genomic-era
#10
REVIEW
Sixto M Leal, Margaret L Gulley
Laboratory tests have a key role in preventing human papillomavirus (HPV)-driven carcinomas and in guiding therapeutic interventions. An understanding of the virology, immunology, and carcinogenesis of HPV is essential for choosing appropriate diagnostic test modalities and developing new and even more effective cancer prevention strategies. HPV infects basal epithelial cells on multiple surfaces and induces carcinoma primarily in the cervix and the oropharynx. HPV types are stratified as high risk or low risk based on their carcinogenic potential, driven largely by viral interference with cell cycle regulation and the DNA damage response to promote continuous cell division while thwarting apoptosis, which enables mutation accumulation...
March 18, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/28325620/hpv-16-variants-impact-on-uterine-cervical-cancer-response-to-radiotherapy-a-descriptive-pilot-study
#11
P Moreno-Acosta, A Vallard, M Molano, A Huertas, Ó Gamboa, M Cotes, A Romero-Rojas, C Rancoule, N Magné
PURPOSE: Although the large impact of Human papilloma virus (HPV) in cervical cancer is established, its place as a therapeutic target is new and according to the growing literature, could be promising. In the present study, radiosensitivity's difference based on HPV-16 variants is assessed. PATIENTS AND METHODS: Variants of Human papilloma virus were identified before the exclusive radiotherapy in patients with cervical cancer. Data were prospectively collected...
March 18, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28324180/lateral-pharyngotomy-approach-in-the-treatment-of-oropharyngeal-carcinoma
#12
Andy Bertolin, Guido Ghirardo, Marco Lionello, Luciano Giacomelli, Marco Lucioni, Giuseppe Rizzotto
Surgery for early-intermediate oropharyngeal squamous cell carcinoma (OPSCC) may involve using transoral endoscopic approaches or open surgical procedures. "Lateral pharyngotomy" (LP) is an open surgical approach that improves exposure of the oropharyngeal region, while avoiding mandibulotomy. The aim of the present study was to retrospectively analyze our experience with the surgical treatment of early-intermediate OPSCC using the LP approach, and to investigate the potentially prognostic clinical and/or pathological factors that might identify patients at higher risk of recurrence after primary surgery...
March 21, 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/28323338/the-prognostic-value-of-extranodal-extension-in-human-papillomavirus-associated-oropharyngeal-squamous-cell-carcinoma
#13
Yi An, Henry S Park, Jacqueline R Kelly, John M Stahl, Wendell G Yarbrough, Barbara A Burtness, Joseph N Contessa, Roy H Decker, Matthew Koshy, Zain A Husain
BACKGROUND: Extranodal (or extracapsular) extension (ENE) is an adverse prognostic factor in patients with head and neck cancers who undergo primary surgery. However, the significance of ENE in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is not well established, and single-institution studies have not established that ENE predicts inferior outcome. The authors investigated the prognostic value of ENE in HPV-positive patients who underwent primary surgery and whether adjuvant chemoradiation improved overall survival (OS) compared with radiation alone in ENE-positive patients...
March 21, 2017: Cancer
https://www.readbyqxmd.com/read/28319456/reactogenicity-of-cervarix-and-gardasil-human-papillomavirus-hpv-vaccines-in-a-randomized-single-blind-trial-in-healthy-uk-adolescent-females
#14
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies...
March 20, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28316084/sensitivity-and-specificity-of-antibodies-against-hpv16-e6-and-other-early-proteins-for-the-detection-of-hpv16-driven-oropharyngeal-squamous-cell-carcinoma
#15
Dana Holzinger, Gunnar Wichmann, Lorena Baboci, Angelika Michel, Daniela Höfler, Manuel Wiesenfarth, Lea Schroeder, Paolo Boscolo-Rizzo, Christel Herold-Mende, Gerhard Dyckhoff, Andreas Boehm, Annarosa Del Mistro, Franz X Bosch, Andreas Dietz, Michael Pawlita, Tim Waterboer
To determine the sensitivity and specificity of HPV16 serology as diagnostic marker for HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), 214 HNSCC patients from Germany and Italy with fresh-frozen tumor tissues and sera collected before treatment were included in this study. 120 cancer cases were from the oropharynx and 94 were from head and neck cancer regions outside the oropharynx (45 oral cavity, 12 hypopharynx and 35 larynx). Serum antibodies to early (E1, E2, E6 and E7) and late (L1) HPV16 proteins were analyzed by multiplex serology and were compared to tumor HPV RNA status as the gold standard...
March 18, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28304083/influence-of-human-papillomavirus-on-the-clinical-presentation-of-oropharyngeal-carcinoma-in-the-united-states
#16
Matthew H Stenmark, Dean Shumway, Cui Guo, Jeffrey Vainshtein, Michelle Mierzwa, Reshma Jagsi, Jennifer J Griggs, Mousumi Banerjee
OBJECTIVE: Much of what is known about the significance of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma is derived from single-institution retrospective studies, post hoc analyses of tissue specimens from clinical trials, and tissue bank studies with a small sample size. The objective of this study is to investigate the impact of HPV on the frequency and clinical presentation of oropharyngeal carcinoma in a large, national sample with information from patients who underwent HPV testing...
March 17, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28302536/rna-chromogenic-in-situ-hybridization-assay-with-clinical-automated-platform-is-a-sensitive-method-in-detecting-high-risk-human-papillomavirus-in-squamous-cell-carcinoma
#17
Javier E Mendez-Pena, Peter M Sadow, Vania Nose, Mai P Hoang
Detection of active human papillomavirus (HPV) is clinically important, as its presence has been shown to correlate with favorable clinical outcomes and better response to treatment in oropharyngeal squamous cell carcinomas (SCC). Using a clinical automated platform, we compared the performance of commercially available HPV DNA and RNA in situ hybridization (ISH) probes in archival tissues of 57 SCC. Importantly, a clinical automated platform gives 1) consistent and reproducible results for HPV ISH and 2) better standardization across clinical laboratories...
March 13, 2017: Human Pathology
https://www.readbyqxmd.com/read/28301611/gtl001-a-bivalent-therapeutic-vaccine-against-human-papillomavirus-16-and-18-induces-antigen-specific-cd8-t-cell-responses-leading-to-tumor-regression
#18
Michaël Esquerré, Myriam Bouillette-Marussig, Anne Goubier, Marie Momot, Christophe Gonindard, Hélène Keller, Astrid Navarro, Marie-Christine Bissery
BACKGROUND: Prophylactic vaccines are available for women and girls not yet infected with HPV, but women already infected with HPV need a treatment to prevent progression to high-grade cervical lesions and cancer. GTL001 is a bivalent therapeutic vaccine for eradicating HPV-infected cells that contains HPV16 E7 and HPV18 E7 both fused to detoxified adenylate cyclase from Bordetella pertussis, which binds specifically to CD11b+ antigen-presenting cells. This study examined the ability of therapeutic vaccination with GTL001 adjuvanted with topical imiquimod cream to induce functional HPV16 E7- and HPV18 E7-specific CD8+ T cell responses...
2017: PloS One
https://www.readbyqxmd.com/read/28295222/traf3-cyld-mutations-identify-a-distinct-subset-of-human-papilloma-virus-associated-head-and-neck-squamous-cell-carcinoma
#19
Michael Hajek, Andrew Sewell, Susan Kaech, Barbara Burtness, Wendell G Yarbrough, Natalia Issaeva
BACKGROUND: The incidence of human papillomavirus (HPV)-associated (HPV-positive) head and neck squamous cell carcinoma (HNSCC) of the oropharynx has dramatically increased over the last decade and continues to rise. Newly diagnosed HPV-positive HNSCCs in the United States currently outnumber any other HPV-associated cancers, including cervical cancer. Despite introduction of the HPV vaccine, the epidemic of HPV-positive HNSCC is expected to continue for approximately 60 years. Compared with patients who have tobacco-associated HNSCC, those who have HPV-positive HNSCC have better overall survival and response to treatment...
March 13, 2017: Cancer
https://www.readbyqxmd.com/read/28285845/a-stratified-randomized-double-blind-phase-ii-trial-of-celecoxib-for-treating-patients-with-cervical-intraepithelial-neoplasia-the-potential-predictive-value-of-vegf-serum-levels-an-nrg-oncology-gynecologic-oncology-group-study
#20
Janet S Rader, Michael W Sill, Jan H Beumer, Heather A Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J Tate Thigpen, Richard Lieberman, Rosemary E Zuna, Charles A Leath, Nick M Spirtos, John Byron, Premal H Thaker, Shashikant Lele, David Alberts
PURPOSE: To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers. PATIENTS AND METHODS: Patients with CIN 3 were randomized to celecoxib 400mg once daily (67 patients) or placebo (63 patients) for 14-18weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha=10% and 90% power when the treatment arm boosted the probability of success by 30%...
March 9, 2017: Gynecologic Oncology
keyword
keyword
23113
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"